Solventum Co. (NYSE:SOLV) Shares Acquired by New York Life Investment Management LLC

New York Life Investment Management LLC raised its holdings in shares of Solventum Co. (NYSE:SOLV) by 0.7% in the 4th quarter, HoldingsChannel reports. The fund owned 18,506 shares of the company’s stock after buying an additional 136 shares during the quarter. New York Life Investment Management LLC’s holdings in Solventum were worth $1,223,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Trian Fund Management L.P. lifted its holdings in shares of Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the last quarter. State Street Corp lifted its holdings in shares of Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Solventum by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock valued at $232,608,000 after purchasing an additional 128,317 shares during the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Solventum in the 3rd quarter valued at about $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Solventum by 0.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after purchasing an additional 3,745 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SOLV. Bank of America boosted their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Wells Fargo & Company boosted their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday. The Goldman Sachs Group upped their price objective on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday. Morgan Stanley upped their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, Mizuho upped their price objective on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $78.86.

Solventum Stock Performance

Shares of SOLV stock opened at $80.07 on Tuesday. The company has a market cap of $13.83 billion and a price-to-earnings ratio of 29.12. The stock has a 50 day simple moving average of $72.78 and a 200-day simple moving average of $70.20. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.